US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Candid Therapeutics, Inc.

News headline image
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
From Candid Therapeutics, Inc.
Via Business Wire
Tickers RLYB
News headline image
Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases
From Candid Therapeutics, Inc.
Via Business Wire
News headline image
Candid Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th
From Candid Therapeutics, Inc.
Via Business Wire
News headline image
Candid Therapeutics Recognized as a 2025 Endpoints 11 Honoree
From Candid Therapeutics, Inc.
Via Business Wire
News headline image
Candid Therapeutics to Participate in Investor and Policy Conferences
From Candid Therapeutics, Inc.
Via Business Wire
News headline image
Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation
From Candid Therapeutics, Inc.
Via Business Wire
News headline image
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
From Candid Therapeutics, Inc.
Via Business Wire
News headline image
Candid Therapeutics and Ab Studio Enter Into Research Collaboration to Discover and Develop Novel T Cell Engagers for Autoimmune Indications
From Candid Therapeutics, Inc.
Via Business Wire
News headline image
Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications
From Candid Therapeutics, Inc.
Via Business Wire
News headline image
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors
From Candid Therapeutics, Inc.
Via Business Wire
News headline image
Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies
From Candid Therapeutics, Inc.
Via Business Wire